These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 25468719)

  • 1. Lifting the mantle: Unveiling new treatment approaches in relapsed or refractory mantle cell lymphoma.
    Mussetti A; Kumar A; Dahi PB; Perales MA; Sauter CS
    Blood Rev; 2015 May; 29(3):143-52. PubMed ID: 25468719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current treatment strategies in relapsed/refractory mantle cell lymphoma: where are we now?
    Atilla E; Atilla PA; Demirer T
    Int J Hematol; 2017 Mar; 105(3):257-264. PubMed ID: 27995456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of allogeneic stem cell transplantation in mantle cell lymphoma.
    Cohen JB; Burns LJ; Bachanova V
    Eur J Haematol; 2015 Apr; 94(4):290-7. PubMed ID: 25154430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma.
    William BM; Allen MS; Loberiza FR; Bociek RG; Bierman PJ; Armitage JO; Vose JM
    Biol Blood Marrow Transplant; 2014 Apr; 20(4):536-42. PubMed ID: 24434781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment for mantle cell lymphoma].
    Izutsu K
    Rinsho Ketsueki; 2017; 58(10):2026-2032. PubMed ID: 28978845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Refining the Mantle Cell Lymphoma Paradigm: Impact of Novel Therapies on Current Practice.
    Avivi I; Goy A
    Clin Cancer Res; 2015 Sep; 21(17):3853-61. PubMed ID: 26059189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of relapsed/refractory mantle cell lymphoma: a review of current therapeutic strategies.
    Zaja F; Federico M; Vitolo U; Zinzani PL
    Leuk Lymphoma; 2014 May; 55(5):988-98. PubMed ID: 23865835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is hematopoietic cell transplantation still a valid option for mantle cell lymphoma in first remission in the chemoimmunotherapy-era?
    Chaudhary L; Kharfan-Dabaja MA; Hari P; Hamadani M
    Bone Marrow Transplant; 2013 Nov; 48(12):1489-96. PubMed ID: 23584438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dexa-BEAM: an effective regimen for cytoreduction prior to high-dose chemotherapy with autologous stem cell support for patients with relapsed/refractory mantle-cell lymphoma.
    Josting A; Reiser M; Wickramanayake PD; Rueffer U; Draube A; Söhngen D; Tesch H; Wolf J; Diehl V; Engert A
    Leuk Lymphoma; 2000 Mar; 37(1-2):185-7. PubMed ID: 10721785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma.
    Mangel J; Buckstein R; Imrie K; Spaner D; Crump M; Tompkins K; Reis M; Perez-Ordonez B; Deodhare S; Romans R; Pennell N; Robinson JB; Hewitt K; Richardson P; Lima A; Pavlin P; Berinstein NL
    Semin Oncol; 2002 Feb; 29(1 Suppl 2):56-69. PubMed ID: 11842390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Review of Autologous Stem Cell Transplantation in Lymphoma.
    Zahid U; Akbar F; Amaraneni A; Husnain M; Chan O; Riaz IB; McBride A; Iftikhar A; Anwer F
    Curr Hematol Malig Rep; 2017 Jun; 12(3):217-226. PubMed ID: 28478586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful allogeneic stem-cell transplantation with prophylactic stepwise G-CSF primed-DLIs for relapse after autologous transplantation in mantle cell lymphoma: a case report and literature review on the evidence of GVL effects in MCL.
    Sohn SK; Baek JH; Kim DH; Jung JT; Kwak DS; Park SH; Suh JS; Lee KB
    Am J Hematol; 2000 Sep; 65(1):75-80. PubMed ID: 10936869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SOHO State of the Art Updates and Next Questions: Treatment Evolution of Mantle Cell Lymphoma: Navigating the Different Entities and Biological Heterogeneity of Mantle Cell Lymphoma in 2024.
    Ip A; Della Pia A; Goy AH
    Clin Lymphoma Myeloma Leuk; 2024 Aug; 24(8):491-505. PubMed ID: 38493059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of hematopoietic stem cell transplantation in patients with relapsed or refractory mantle cell lymphoma.
    Yamasaki S; Chihara D; Kim SW; Izutsu K; Iwato K; Fukuda T; Uchida N; Amano I; Nakazawa H; Kuroda J; Hashimoto H; Ichinohe T; Kanda Y; Atsuta Y; Suzumiya J; Suzuki R
    Ann Hematol; 2018 Aug; 97(8):1445-1452. PubMed ID: 29610968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real-world experience.
    Jeon YW; Yoon S; Min GJ; Park SS; Park S; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Lee JW; Cho SG
    Cancer Med; 2019 Nov; 8(16):6860-6870. PubMed ID: 31560165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL).
    Dawar R; Hernandez-Ilizaliturri F
    Best Pract Res Clin Haematol; 2012 Jun; 25(2):185-90. PubMed ID: 22687454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial.
    Rummel M; Kaiser U; Balser C; Stauch M; Brugger W; Welslau M; Niederle N; Losem C; Boeck HP; Weidmann E; von Gruenhagen U; Mueller L; Sandherr M; Hahn L; Vereshchagina J; Kauff F; Blau W; Hinke A; Barth J;
    Lancet Oncol; 2016 Jan; 17(1):57-66. PubMed ID: 26655425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cisplatin, fludarabine, and cytarabine: a novel, pharmacologically designed salvage therapy for patients with refractory, histologically aggressive or mantle cell non-Hodgkin's lymphoma.
    Seymour JF; Grigg AP; Szer J; Fox RM
    Cancer; 2002 Feb; 94(3):585-93. PubMed ID: 11857288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of bendamustine combined with rituximab in relapsed/refractory mantle cell lymphoma: efficacy, tolerability, and safety findings.
    Czuczman MS; Goy A; Lamonica D; Graf DA; Munteanu MC; van der Jagt RH
    Ann Hematol; 2015 Dec; 94(12):2025-32. PubMed ID: 26411584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autologous and allogeneic stem cell transplantation: rising therapeutic promise for mantle cell lymphoma.
    Tam CS; Khouri IF
    Leuk Lymphoma; 2009 Aug; 50(8):1239-48. PubMed ID: 19562639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.